Published online before print August 23, 2004, doi: 10.1161/01.HYP.0000142169.17298.54
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;44:459.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
Prognostic Significance of Electrocardiographic Voltages and Their Serial Changes in Elderly With Systolic Hypertension
From the Hypertension and Cardiovascular Rehabilitation Unit (R.H.F., J.A.S., L.T., H.C.), University of Leuven, Leuven, Belgium; Erasmus University (W.H.B.), Rotterdam, the Netherlands; Imperial College, Hammersmith Hospital (C.J.B.), London, UK; University of Maastricht (P.W.d.L.), Maastricht, the Netherlands; Istituto Auxologico Italiano (G.L.), Ospedale San Luca, Milano, Italy; National Public Health Institute and the University of Helsinki (C.S., J.T.), Helsinki, Finland; Clinical Pharmacology Unit (J.W.), Aberdeen Royal Infirmary, Aberdeen, UK; Department of Family Medicine (Y.Y.), Hadassah Medical School, Hebrew University of Jerusalem, Jerusalem, Israel.
Correspondence to R. Fagard, MD, PhD, Professor of Medicine, Hypertension and Cardiovascular Rehabilitation Unit, U.Z.Gasthuisberg-Hypertensie, Herestraat 49, B-3000 Leuven, Belgium. E-mail robert.fagard{at}uz.kuleuven.ac.be
The aim of the present study was to assess the prognostic value of ECG voltages at baseline and their serial changes during follow-up in a large prospective study with standardized follow-up and strictly defined end points. Patients who were 60 years old or older, with systolic blood pressure of 160 to 219 mm Hg and diastolic pressure <95 mm Hg, were randomized into the double-blind placebo-controlled Systolic Hypertension in Europe trial. Active treatment consisted of nitrendipine, which could be combined with or replaced by enalapril, hydrochlorothiazide, or both. At the end of the double-blind part of the trial (median follow-up, 2.0 years), follow-up was extended and all patients received active study drugs (median total follow-up, 6.1 years). Electrocardiography was performed at baseline and yearly thereafter. Electrocardiographic left ventricular mass was prospectively defined as the sum of 3 voltages (RaVL+SV1+RV5), which averaged 3.1±1.0 mV. The adjusted relative hazard rate, associated with a 1 mV higher sum at baseline, amounted to 1.10 and 1.15 for all-cause and cardiovascular mortality and to 1.21 and 1.18 for strokes and cardiac events, respectively (P
0.01 for all). A 1-mV decrease in electrocardiographic voltages during follow-up independently predicted a lower incidence of cardiac events (relative hazard rate: 0.86; P0.05), but not of stroke or mortality. In conclusion, electrocardiographic voltages at baseline and their serial changes during follow-up predict subsequent events in older patients with systolic hypertension.
Key Words: antihypertensive therapy • elderly • electrocardiography • hypertension, essential • hypertrophy, cardiac • prognosis
This article has been cited by other articles:
 |
|
 |
|
  R. H. Fagard, H. Celis, L. Thijs, and S. Wouters Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies Hypertension, November 1, 2009; 54(5): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Verdecchia, P. Sleight, G. Mancia, R. Fagard, B. Trimarco, R. E. Schmieder, J.-H. Kim, G. Jennings, P. Jansky, J.-H. Chen, et al. Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease Circulation, October 6, 2009; 120(14): 1380 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, L. Oikarinen, M. Viitasalo, L. Toivonen, S. E. Kjeldsen, M. S. Nieminen, J. M. Edelman, B. Dahlof, R. B. Devereux, and for the LIFE Study Investigators Prognostic Value of Changes in the Electrocardiographic Strain Pattern During Antihypertensive Treatment: The Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE) Circulation, April 14, 2009; 119(14): 1883 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Okin, R. B. Devereux, K. E. Harris, S. Jern, S. E. Kjeldsen, S. Julius, J. M. Edelman, B. Dahlof, and for the LIFE Study Investigators Regression of Electrocardiographic Left Ventricular Hypertrophy Is Associated with Less Hospitalization for Heart Failure in Hypertensive Patients Ann Intern Med, September 4, 2007; 147(5): 311 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
A. Delgado-Almeida, M. P. Schneider, R. E. Schmieder, R. H. Fagard, and on behalf of the Syst-Eur investigators Critical Value of the Electrocardiogram in LVH: From Predictive Index to Therapeutic Reassessment Hypertension, February 1, 2005; 45(2): e6 - e7. [Full Text] [PDF]
|
|